Cargando…

Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies

AIMS: Examine relationships between the systemic exposure of acalabrutinib, a highly selective, next‐generation Bruton tyrosine kinase inhibitor, and its active metabolite (ACP‐5862) vs. efficacy and safety responses in patients with B‐cell malignancies who received acalabrutinib as monotherapy or i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edlund, Helena, Buil‐Bruna, Núria, Vishwanathan, Karthick, Wei, Helen, Raman, Rakesh, de Kock, Miné, He, Zhongqing, Liu, Huan, Baek, Marshall, Ware, Joseph, Patel, Priti, Tomkinson, Helen, Sharma, Shringi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298019/ https://www.ncbi.nlm.nih.gov/pubmed/34532877 http://dx.doi.org/10.1111/bcp.15087

Ejemplares similares

Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach
por: Edlund, Helena, et al.
Publicado: (2021)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
por: Zhou, Diansong, et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
por: Wu, Jingjing, et al.
Publicado: (2016)

Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
por: Sharma, Shringi, et al.
Publicado: (2022)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors
por: Pilla Reddy , Venkatesh, et al.
Publicado: (2021)

Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study
por: Strati, Paolo, et al.
Publicado: (2021)

The Interactions of CPP–ACP with Saliva
por: Huq, Noorjahan Laila, et al.
Publicado: (2016)

Acalabrutinib: Disseminated aspergillosis: case report
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Institutional and Cultural Barriers to ACP: Staff Perspectives
por: Gutman, Gloria, et al.
Publicado: (2020)

Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
por: Jurczak, Wojciech, et al.
Publicado: (2023)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB1948: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, Tatyana, et al.
Publicado: (2023)

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2023)

A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M(27) in human plasma and application to a human pharmacokinetic study
por: Valluri, Venkat Rao, et al.
Publicado: (2022)

ACP basic statistics = ACP, statistiques de base.
Publicado: (1985)

Enamel defects in Acp4(R110C/R110C) mice and human ACP4 mutations
por: Liang, Tian, et al.
Publicado: (2022)

Educational Intervention for Care Home Staff to Encourage Resident ACP
por: Soheilipour, Shimae, et al.
Publicado: (2020)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
por: Series, Jennifer, et al.
Publicado: (2019)

Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective
por: Sood, Nitin, et al.
Publicado: (2021)

Acalabrutinib in Membranous Nephropathy Associated With Chronic Lymphocytic Leukemia
por: Izzedine, Hassan, et al.
Publicado: (2022)

GCNCPR-ACPs: a novel graph convolution network method for ACPs prediction
por: Wu, Xiujin, et al.
Publicado: (2022)

DLFF-ACP: prediction of ACPs based on deep learning and multi-view features fusion
por: Cao, Ruifen, et al.
Publicado: (2021)

Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
por: Vitale, Candida, et al.
Publicado: (2021)

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
por: Bye, Alexander P., et al.
Publicado: (2022)

ACP medicine : a publication of the American College of Physicians /
Publicado: (2004)

Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
por: Izutsu, Koji, et al.
Publicado: (2021)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

Cultural and Institutional Issues in ACP for Care Home Residents: Perspectives of Loved Ones
por: de Vries, Brian, et al.
Publicado: (2020)

Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib
por: Lin, David Y., et al.
Publicado: (2023)

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
por: Overman, Michael, et al.
Publicado: (2020)

ACP Conference on Fundamental Physics of Ferroelectrics
por: Cohen, Ronald E
Publicado: (2000)

Maryland ACP Winning Abstracts 2017
Publicado: (2017)

Intraarticular ACP therapy for severe osteoarthritis
por: Borsky, Michael
Publicado: (2019)

Shewanella oneidensis FabB: A β-ketoacyl-ACP Synthase That Works with C16:1-ACP
por: Luo, Qixia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_72t6fh1aa2ft3h2bln9el6m8fl